{
    "clinical_study": {
        "@rank": "114279", 
        "arm_group": [
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }, 
            {
                "arm_group_label": "co-amoxiclav", 
                "arm_group_type": "Experimental", 
                "description": "co-amoxiclav is a combination antibiotic consisting of amoxicillin trihydrate, a \u03b2-lactam antibiotic, and potassium clavulanate, a \u03b2-lactamase inhibitor"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to evaluate if a single i.v. dose of co-amoxiclav before PEG can\n      reduce the incidence of peristomal wound infection in the paediatric population."
        }, 
        "brief_title": "Antibiotic Prophylaxis for PEG in Children", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Infection", 
        "detailed_description": {
            "textblock": "Percutaneous  Endoscopic  Gastrostomy (PEG) is a common endoscopic procedure, performed to\n      avoid malnutrition in various pathological conditions.\n\n      Gastrostomy tube placement is associated with intra and postoperative complications both in\n      the adult and in the paediatric population.\n\n      Local infection is the most common complication following PEG.\n\n      Antibiotic prophylaxis is a well-established strategy to reduce peristomal wound infection\n      rate in adult population.\n\n      The aim of this study is to evaluate if a single i.v. dose of co-amoxiclav before PEG can\n      reduce the incidence of peristomal wound infection in the paediatric population."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All pediatric patients (0-18 years) who will refer for PEG placement to the endoscopy\n             unit\n\n        Exclusion Criteria:\n\n          -  Controindications for PEG\n\n          -  Ongoing antibiotic treatment\n\n          -  Antibiotic use within the past 4 days\n\n          -  Illness too severe to allow the patient to participate\n\n          -  Allergy to penicillin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "1 Month"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01870167", 
            "org_study_id": "Pediatric- PEG"
        }, 
        "intervention": [
            {
                "arm_group_label": "co-amoxiclav", 
                "description": "a single iv dose of co-amoxiclav (50/mg/Kg) at the time of PEG insertion.", 
                "intervention_name": "co-amoxiclav", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Bacterial Agents", 
                "Amoxicillin-Potassium Clavulanate Combination", 
                "Antibiotics, Antitubercular"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "PEG", 
            "Percutaneous  Endoscopic  Gastrostomy", 
            "antibiotic prophylaxis"
        ], 
        "lastchanged_date": "June 4, 2013", 
        "location": {
            "contact": {
                "email": "giovanni.dinardo@uniroma1.it", 
                "last_name": "Department of Pediatrics", 
                "phone": "0649979326"
            }, 
            "facility": {
                "address": {
                    "city": "Rome", 
                    "country": "Italy", 
                    "zip": "00161"
                }, 
                "name": "Department of Pediatrics"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Antibiotic Prophylaxis for Percutaneous Endoscopic Gastrostomy (PEG) in Children: a Randomised Controlled Trial.", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "24 hours after PEG insertion PEG site will be examined for erythema, induration and exudate and scored using the peristomal sepsis scoring system.\nPEG site infection will be defined as presence of pus or a score of 8 or more, with or without microbiological evidence of bacterial or fungal infection from PEG site swabs.", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "24 hours after PEG insertion"
            }, 
            {
                "description": "14 days after PEG insertion PEG site will be examined for erythema, induration and exudate and scored using the peristomal sepsis scoring system.", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "14 days after PEG insertion"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01870167"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Azienda Policlinico Umberto I", 
            "investigator_full_name": "Giovanni Di Nardo", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Secondary outcomes are occurrence of systemic infection, defined as persistent fever (temperature >38.0 \u00b0C for >24 h) or clinical, laboratory and microbiological evidence of invasive sepsis and objective signs of infection, including a positive bacterial or fungal culture, high levels of highly sensitive C reactive protein, and a high white blood cell count.", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "24 hours after PEG insertion"
            }, 
            {
                "description": "Secondary outcomes are occurrence of systemic infection, defined as persistent fever (temperature >38.0 \u00b0C for >24 h) or clinical, laboratory and microbiological evidence of invasive sepsis and objective signs of infection, including a positive bacterial or fungal culture, high levels of highly sensitive C reactive protein, and a high white blood cell count.", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "14 days after PEG insertion"
            }
        ], 
        "source": "Azienda Policlinico Umberto I", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Azienda Policlinico Umberto I", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}